544210 Stock Overview
Engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 544210 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Emcure Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,288.65 |
| 52 Week High | ₹1,577.50 |
| 52 Week Low | ₹890.00 |
| Beta | 0 |
| 1 Month Change | 17.21% |
| 3 Month Change | 29.29% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 544210 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 21.1% | -0.04% | -0.2% |
| 1Y | n/a | 13.1% | 2.2% |
Return vs Industry: Insufficient data to determine how 544210 performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 544210 performed against the Indian Market.
Price Volatility
| 544210 volatility | |
|---|---|
| 544210 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 544210 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 544210's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 10,852 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems.
Emcure Pharmaceuticals Limited Fundamentals Summary
| 544210 fundamental statistics | |
|---|---|
| Market cap | ₹243.37b |
| Earnings (TTM) | ₹6.81b |
| Revenue (TTM) | ₹79.63b |
Is 544210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 544210 income statement (TTM) | |
|---|---|
| Revenue | ₹79.63b |
| Cost of Revenue | ₹31.47b |
| Gross Profit | ₹48.17b |
| Other Expenses | ₹41.35b |
| Earnings | ₹6.81b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 35.96 |
| Gross Margin | 60.49% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 15.8% |
How did 544210 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 07:36 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emcure Pharmaceuticals Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alok Dalal | Jefferies LLC |
| Bansi Desai | J.P. Morgan |
| Alankar Garude | Kotak Securities (Institutional Equities) |